🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excellent 👌

Love this! One of the most novel ways to clearly deliver a message in a manuscript (pun intended)

When science reads like a national security report... Congrats Manni Mohyuddin et al!

This study highlights the rise in protocol redactions and predicts that, ██████████████████████████████████████████ will be entirely redacted between 2073 and 2136 #ChristmasBMJ bmj.com/content/383/bm…

This year's best 🎄🧑‍🎄 article from The BMJ is the RAPTURE : Complete redaction of clinical trial protocols expected somewhere between 2073 and 2136 😂 bmj.com/content/383/bm…

Redactions in clinical trial protocols are █████████████████████. What did this partially redacted study find about redactions in clinical trials? #ChristmasBMJ bmj.com/content/383/bm…

Big problem of IO access in control arm as trial was performed in countries lacking access. 40% of patients in control arm who got systemic therapy at relapse didn’t get IO. Censoring also an issue. The “positive” OS isn’t real. More info here…..ascopubs.org/doi/full/10.12…

Our new paper on class effects in oncology. A great opportunity for savings for health care payers, without impacting outcomes.

Read this paper carefully. Then read it again. It will open your mind up about censoring in ways you prob have never thought about. A true gem. Must read for all. ejcancer.com/article/S0959-… Numerous myeloma trials (belantamab!) susceptible to this! #mmsm Vinay Prasad MD MPH

One of my favorite paper with Vinay ! One goal : to make informative censoring considered as important as the control arm or post-progression therapy ! Check out the paper (open access)👇 + More to come soon !

The Q of whether dietary interventions help people with cancer is very imp. RCTs are the gold standard for evaluating interventions. What do RCTs of dietary interventions in cancer tell us? We eval in this systematic review of all dietary RCTs 1/🧵 pubmed.ncbi.nlm.nih.gov/38429997/

Forget laser pointer, you can’t fit 2 molecules of oxygen between these curves! #monarchE update.

Excited to share our new study finding that the quality of subgroup analyses and claims for differential treatment effects in modern phase III oncology trials remains low, increasing risk of misinterpretation. More use of frameworks such as ICEMAN may improve future quality.

NATALEE phase 3 trial... deserves a sensitivity analyis ! remember the monarchE trial (adjuvant abemaciclib for 2⃣ years) --> now we have NATALEE with adjuvant ribociclib for 3⃣ years ‼️ iDFS benefit ! ... but let's have a closer look ! 1/🧵

informative censoring was raised by Tomer Meirson et al. in their nice work about monarchE ❗️ check it out : thelancet.com/journals/lanon… 7/

Our new paper - the tyranny of non-inferiority.

Ever wondered why the results of 3 immunotherapy trials in urothelial cancers are different? Is it truly because the 3 drugs are different? In this smart study led by Tomer Meirson , we show that these differences can all be explained by differential censoring alone!

Bishal Gyawali, MD, PhD, FASCO Tomer Meirson To my mind, differential censoring is an important, under-recognised issue in clinical trials. This is a very nice demonstration of how it could affect trial results

Now Online! CSO RCT Checklist. Common Sense Oncology RCT team has just published in The Lancet Oncology a CHECKLIST to design and report cancer drug RCTs. You know about CONSORT checklist for RCTs but this CSO checklist is specifically for cancer drug RCTs and incorporates items such as

x.com/i/article/1928…